– 14% year-over-year revenue increase from combined key growth drivers:Xywav®, Epidiolex® and Rylaze® –– 2024 total revenue guidance affirmed at $4.0 to $4.1 billion –– Zanidatamab 2L BTC PDUFA date of November 29, 2024 –– Plan to submit sNDA for Zepzelca® in 1L ES-SCLC in 1H25 –DUBLIN, Nov. 6, 2024  /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2024 and updated guidance for 2024."Jazz once again delivered record revenues of more than $1.0 ...

Core Insights - The Ritz-Carlton, Naples is hosting its inaugural "NYE Black-Tie Gala" on New Year's Eve, featuring a luxurious five-course dinner and live jazz performances by Stella Cole, marking a significant addition to the resort's event offerings [2][3]. Event Details - The gala includes a 'Meet the Artist' reception, a five-course dinner curated by Executive Chef Satish Yerramilli, and a live performance by Stella Cole, culminating in a midnight countdown [4][5]. - Guests can enjoy premium bar selections and receive an autographed album of Stella Cole's debut release [5]. Ticket Pricing - Ticket options include Premiere Seating at $650 per person, Reserved Seating at $525 per person, and Large Table Reservations starting from $500 per person, all packages inclusive of taxes, gratuity, and valet parking [7]. Room Reservations - An exclusive "NYE Black-Tie Gala" package is available, which includes an overnight stay in a Coastal View Guestroom and two reserved seating-level tickets for the gala [8]. About The Ritz-Carlton, Naples - The Ritz-Carlton, Naples is a luxury resort featuring 474 guest rooms, a newly renovated Vanderbilt Tower, and various dining venues, recognized for its high standards and numerous accolades [10].

DUBLIN, Oct. 23, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 third quarter financial results on Wednesday, November 6, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss 2024 third quarter financial results and provide a business and financial update.  Audio webcast/conference call: U.S. Dial-In Number: +1 800 715 9871Ireland Dial-In Number: +353 1800 9 ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks. Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at ...

Investors interested in Medical - Drugs stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Zoetis (ZTS) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with speci ...

Core Viewpoint - Jazz Pharmaceuticals' shares increased nearly 6% following positive results from the phase III IMforte study, which evaluated the combination of Zepzelca and Roche's Tecentriq in treating extensive-stage small cell lung cancer [1][2]. Group 1: Study Results - The IMforte study demonstrated statistically significant improvements in overall survival and progression-free survival for the Zepzelca-Tecentriq combination compared to Tecentriq alone [2]. - The combination therapy was well-tolerated among participants, with no new safety signals reported [2]. Group 2: Regulatory Plans - Jazz Pharmaceuticals plans to submit a regulatory filing in the first half of 2025 for the Zepzelca-Tecentriq combination as a first-line maintenance treatment for extensive-stage small cell lung cancer [3]. - PharmaMar, which licensed Zepzelca to Jazz, also intends to submit a regulatory filing with the EMA for the same combination in the first half of 2025 [4]. Group 3: Current Market Performance - Year-to-date, Jazz Pharmaceuticals' shares have decreased by 4.6%, while the industry has seen a decline of 2.9% [3]. - Jazz's Zepzelca has been under accelerated FDA approval since 2020 for treating adult patients with metastatic small-cell lung cancer previously treated with platinum-based chemotherapy [3]. Group 4: Future Studies - The company is currently conducting the confirmatory phase III LAGOON study to evaluate Zepzelca for patients with relapsed small cell lung cancer, with plans to convert accelerated approval to full approval if results are positive [3].

Group 1 - Investors have not fully recognized the significance of two recent legal victories for Jazz Pharmaceuticals, which are expected to enhance the company's long-term prospects [2] - The first legal win was a partial victory against a competitor, indicating a positive shift in the competitive landscape for Jazz Pharmaceuticals [2] Group 2 - The article emphasizes the importance of tracking attractive risk/reward situations in the biotech sector, suggesting that there are potential growth stocks worth considering [2]

Jazz Pharmaceuticals (JAZZ, Financial), a leading player in the narcolepsy market, is expanding its reach into other markets such as the non-small cell lung cancer (NSCLC) market by preparing a new biliary tract cancer drug; Zanidatamab. Zanidatamab that belongs to the NSCLC market is estimated to be worth $32 billion. Capturing even a modest 5% share could translate into $1.6 billion in additional revenue for Jazz. Considering the company's 2023 revenue of $3.8 billion, this represents a substantial growth ...

Jazz Pharmaceuticals (JAZZ) focuses on making drugs for neuroscience and oncology. The company derives most of its revenues from its sleep disorder drugs — Xywav and Xyrem. Xywav is a low-sodium formulation of Jazz's legacy drug, Xyrem. It also has a rapidly growing oncology portfolio. Jazz's revenues continue to benefit from strong demand for newer drugs like Xywav, Epidiolex and Rylaze. Jazz has also regularly boosted its commercial portfolio and pipeline through acquisitions. Jazz boasts a promising pipe ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use a variety of methods, including tried-and-true valuation met ...